Trial Profile
A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jun 2022
Price :
$35
*
At a glance
- Drugs Pitolisant (Primary)
- Indications Cataplexy; Narcolepsy
- Focus Registrational; Therapeutic Use
- Acronyms HARMONY-CTP
- Sponsors Bioprojet
- 06 Jun 2022 According to a Harmony Biopharm media release, results of post hoc, pooled analyses from the HARMONY-1 and HARMONY-CTP trials, was presented at the 36th Annual Meeting of the Associated Professional Sleep Societies (APSS).
- 06 Jun 2022 Results published in the Media Release
- 12 Dec 2021 Results published in the CNS Drugs